Is tezepelumab the ubiquitous biologic for severe asthma?
- PMID: 36702145
- DOI: 10.1016/S2213-2600(22)00530-6
Is tezepelumab the ubiquitous biologic for severe asthma?
Erratum in
-
Correction to Lancet Respir Med 2023; published online Jan 23. https://doi.org/10.1016/S2213-2600(22)00530-6.Lancet Respir Med. 2023 Mar;11(3):e25. doi: 10.1016/S2213-2600(23)00046-2. Epub 2023 Feb 3. Lancet Respir Med. 2023. PMID: 36746167 No abstract available.
Conflict of interest statement
RB declares grant funding to the Medical Research Institute of New Zealand from AstraZeneca, Genentech, and the New Zealand Health Research Council and personal consulting fees from AstraZeneca, Cipla, Avillion, Health Research Council (New Zealand), CSL Seqirus, and Teva Pharmaceuticals. ABC declares no competing interests.
Comment on
-
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study.Lancet Respir Med. 2023 May;11(5):425-438. doi: 10.1016/S2213-2600(22)00492-1. Epub 2023 Jan 23. Lancet Respir Med. 2023. PMID: 36702146 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
